Advertisement
LIVN vs NVST
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIVN is a StrongBuy and NVST is a Buy.
Momentum Indicator for LIVN turns positive, indicating new upward trend
LIVN saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 66 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LIVN just turned positive on October 09, 2026. Looking at past instances where LIVN's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Following a +2.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIVN advanced for three days, in 205 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
LIVN moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
LIVN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LIVN entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LIVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.261) is normal, around the industry mean (2.923). P/E Ratio (22.736) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.899) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.954) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NVST's RSI Indicator ascending out of oversold territory
The RSI Indicator for NVST moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 21 of the 27 cases the stock moved higher. This puts the odds of a move higher at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 69 cases where NVST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NVST as a result. In 69 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for NVST just turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 30 of 51 cases over the following month. The odds of a continued upward trend are 59%.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 176 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
NVST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for NVST entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. NVST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.211) is normal, around the industry mean (4.952). P/E Ratio (39.305) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
LIVN | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 55 | 87 | |
PRICE GROWTH RATING 1..100 | 41 | 59 | |
P/E GROWTH RATING 1..100 | 81 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (62) in the null industry is in the same range as LIVN (78) in the Medical Specialties industry. This means that NVST’s stock grew similarly to LIVN’s over the last 12 months.
NVST's Profit vs Risk Rating (100) in the null industry is in the same range as LIVN (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to LIVN’s over the last 12 months.
LIVN's SMR Rating (55) in the Medical Specialties industry is in the same range as NVST (87) in the null industry. This means that LIVN’s stock grew similarly to NVST’s over the last 12 months.
LIVN's Price Growth Rating (41) in the Medical Specialties industry is in the same range as NVST (59) in the null industry. This means that LIVN’s stock grew similarly to NVST’s over the last 12 months.
LIVN's P/E Growth Rating (81) in the Medical Specialties industry is in the same range as NVST (82) in the null industry. This means that LIVN’s stock grew similarly to NVST’s over the last 12 months.
| LIVN | NVST | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 68% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 71% |
| Advances ODDS (%) | 3 days ago 68% | 2 days ago 65% |
| Declines ODDS (%) | 9 days ago 74% | 4 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 78% | 4 days ago 62% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIVN’s FA Score shows that 0 FA rating(s) are green while NVST’s FA Score has 0 green FA rating(s).
- LIVN’s FA Score: 0 green, 5 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIVN’s TA Score shows that 3 TA indicator(s) are bullish while NVST’s TA Score has 6 bullish TA indicator(s).
- LIVN’s TA Score: 3 bullish, 5 bearish.
- NVST’s TA Score: 6 bullish, 2 bearish.
Price Growth
LIVN (@Medical/Nursing Services) experienced а +3.10% price change this week, while NVST (@Pharmaceuticals: Other) price change was +1.62% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
Reported Earning Dates
LIVN is expected to report earnings on Nov 04, 2026.
NVST is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
LIVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, LIVN has been loosely correlated with CRL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LIVN jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To LIVN | 1D Price Change % | ||
|---|---|---|---|---|
| LIVN | 100% | -1.59% | ||
| CRL - LIVN | 48% Loosely correlated | +9.33% | ||
| NVST - LIVN | 42% Loosely correlated | +0.96% | ||
| A - LIVN | 41% Loosely correlated | +2.74% | ||
| MTD - LIVN | 39% Loosely correlated | +2.69% | ||
| MMSI - LIVN | 39% Loosely correlated | +0.24% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AADR | 81.14 | 0.71 | +0.89% |
| AdvisorShares Dorsey Wright ADR ETF (AADR) | |||
| TILT | 282.01 | 1.37 | +0.49% |
| Northern Trust Morningstar US Market Factor Tilt ETF (TILT) | |||
| KSPY | 30.37 | 0.11 | +0.35% |
| KraneShares Hedgeye Hedged Equity Index ETF (KSPY) | |||
| EPMV | 25.61 | N/A | N/A |
| Harbor Mid Cap Value ETF | |||
| COPY | 15.63 | -0.05 | -0.32% |
| Tweedy Browne Insider + Value ETF Trust Units (COPY) | |||